NewsBenzingaTakeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B Benzinga 2026.10.29 07:57 (GMT+0) Open on Benzinga Other news Merck Beats, But Can Shares Outplay The Cancer Vaccine News? Mizuho Upgrades Hilton Worldwide Holdings to Outperform, Raises Price Target to $421 HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target Top Wall Street Forecasters Revamp Intel Expectations Ahead Of Q3 Earnings UK Department Of Health And Social Care Extends Under-18 Sales Ban To Nicotine Products And All Vapes Needham Maintains Buy on Glaukos, Raises Price Target to $251
UK Department Of Health And Social Care Extends Under-18 Sales Ban To Nicotine Products And All Vapes
